Breast Cancer Clinical Trial
A Study of 1 8F-FDHT PET/MRIScans in Women With Breast Cancer
Summary
The purpose of this study is to see whether 18F-FDHT PET/MRI scans are an effective way of identifying AR-positive breast cancer.
Eligibility Criteria
Inclusion Criteria:
Age ≥ 18 years
ECOG performance score of 0-2
Signed informed consent
Histologically confirmed AR+ breast cancer
All participants under consideration for enrollment will have their tumor specimen tested centrally at MSK; nuclear AR staining ≥ 1% will be considered positive.
Progressive metastatic breast cancer manifested as increase in evaluable disease OR the appearance of new sites of disease since the date of the last imaging study performed and under consideration for AR-targeted therapy
Planning to undergo treatment with agents targeting the antiandrogen signaling pathway on a clinical trial
Exclusion Criteria:
Life expectancy < 3 months
Pregnancy or lactation
Participants who cannot undergo scanning because of
weight limits
devices or implants that are not MRI safe
allergies to contrast materials
CNS only disease on recent imaging
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
How clear is this clinincal trial information?